Achieve Life Sciences Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Achieve Life Sciences in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Achieve Life Sciences stock.
View analyst ratings for Achieve Life Sciences or view top-rated stocks.

Wall Street analysts have given Achieve Life Sciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Achieve Life Sciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Achieve Life Sciences saw a drop in short interest in May. As of May 28th, there was short interest totaling 330,200 shares, a drop of 22.9% from the May 13th total of 428,100 shares. Based on an average trading volume of 124,100 shares, the days-to-cover ratio is presently 2.7 days. Currently, 3.8% of the company's shares are short sold.
View Achieve Life Sciences' Short Interest.

Achieve Life Sciences is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Achieve Life Sciences.

Achieve Life Sciences, Inc. (NASDAQ:ACHV) issued its quarterly earnings results on Wednesday, May, 12th. The biopharmaceutical company reported ($1.30) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.78) by $0.52.
View Achieve Life Sciences' earnings history.

Achieve Life Sciences' stock was trading at $8.3240 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ACHV stock has decreased by 7.3% and is now trading at $7.72.
View which stocks have been most impacted by COVID-19.

Shares of Achieve Life Sciences reverse split on the morning of Friday, July 31st 2020. The 1-20 reverse split was announced on Thursday, July 30th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 30th 2020. An investor that had 100 shares of Achieve Life Sciences stock prior to the reverse split would have 5 shares after the split.

4 equities research analysts have issued 12 month target prices for Achieve Life Sciences' shares. Their forecasts range from $21.00 to $100.00. On average, they anticipate Achieve Life Sciences' share price to reach $50.33 in the next twelve months. This suggests a possible upside of 552.0% from the stock's current price.
View analysts' price targets for Achieve Life Sciences or view top-rated stocks among Wall Street analysts.

Some companies that are related to Achieve Life Sciences include Amgen (AMGN), Gilead Sciences (GILD), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR).
View all of ACHV's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Achieve Life Sciences investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Bionano Genomics (BNGO), Novan (NOVN), Aeterna Zentaris (AEZS), Zosano Pharma (ZSAN), Cannabics Pharmaceuticals (CNBX), KushCo (KSHB) and Pennsylvania Real Estate Investment Trust (PEI).

Achieve Life Sciences trades on the NASDAQ under the ticker symbol "ACHV."

Achieve Life Sciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Morgan Stanley (1.42%), Geode Capital Management LLC (0.48%), Renaissance Technologies LLC (0.36%), Citadel Advisors LLC (0.20%), Citadel Advisors LLC (0.20%) and Paradigm Financial Partners LLC (0.18%).
View institutional ownership trends for Achieve Life Sciences.

ACHV stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, Geode Capital Management LLC, Renaissance Technologies LLC, Citadel Advisors LLC, Citadel Advisors LLC, and Paradigm Financial Partners LLC.
View insider buying and selling activity for Achieve Life Sciences or or view top insider-buying stocks.

Shares of ACHV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ACHV stock can currently be purchased for approximately $7.72.

Achieve Life Sciences has a market capitalization of $47.59 million. The biopharmaceutical company earns $-14,730,000.00 in net income (profit) each year or ($5.42) on an earnings per share basis.

Achieve Life Sciences employs 13 workers across the globe.

The official website for Achieve Life Sciences is achievelifesciences.com.

Achieve Life Sciences is headquartered at 1040 WEST GEORGIA STREET SUITE 1030, VANCOUVER BC, V6E 4H1.

Achieve Life Sciences' mailing address is 1040 WEST GEORGIA STREET SUITE 1030, VANCOUVER BC, V6E 4H1. The biopharmaceutical company can be reached via phone at 604-210-2217 or via email at [email protected]